TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00818363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Placebo
Description: Injectable Solution; 5.0 mL SABER-Placebo/Once
Study: NCT04919902

Intervention type: PROCEDURE
Intervention: Electric cardioversion
Description: Electric cardioversion in short sedation according to established clinical practice and indications
Study: NCT04399356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Telehealth monitoring
Description: In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth monitoring
Description: In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
Study: NCT03214081

Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study: NCT02848261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental Demands
Description: Education and training related to use of CGM in this age group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Reduction
Description: Education and training on reducing distress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Education and training on the use of remote monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear of Hypoglycemia
Description: Education and training on reducing fear of hypoglycemia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention - serves as the control group
Study: NCT00480896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Topical application
Study: NCT00890175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine @ 0 & 10 h
Description: 10 mg, 2 doses, 10 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo @ 2 & 10 hours
Description: placebo, 2 doses, 10 hours apart
Study: NCT03579290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT program
Description: The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~* Understanding and changing patterns of drug use,~* Coping with craving,~* Substance refusal skills,~* Seemingly irrelevant decisions,~* Planning for emergencies, and~* Problem-solving skills.~* Staying Safe
Study: NCT02918500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm Patch
Description: Nicotine replacement therapy patch
Study: NCT01862796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Underfeeding diet
Description: Heart healthy diet with 35% reduced calories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintaining diet
Description: Heart healthy weight-maintaining diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintaining diet
Description: Heart healthy weight-maintaining diet
Study: NCT01336959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197 Part A
Description: open label single dose administration of 10mg BCT197, 2 hours prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose matching placebo administered 2 prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197 Part B
Description: BCT197 50mg single dose administered 2 hours prior to surgery
Study: NCT00640237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-D3
Description: We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
Study: NCT03485911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 capsules
Description: BCX7353 oral capsules administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 capsules
Description: BCX7353 oral capsules administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching oral capsules administered once daily
Study: NCT01994356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician self-disclosure of personal IUC use
Description: Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual contraceptive counseling
Description: all subjects recieved usual contraceptive counseling
Study: NCT02124148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered IV
Study: NCT02326350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75mg
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Placebo
Study: NCT03002038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
Study: NCT03078153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will receive a $50 gift card at 3- and 6- month follow-up visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Group
Description: Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
Study: NCT06339554

Intervention type: DRUG
Intervention: Alectinib 150 MG [Alecensa]
Description: First line treatment for cohorts A and B

Intervention type: DRUG
Intervention: Alectinib 150 MG [Alecensa]
Description: First line treatment for cohorts A and B
Study: NCT01616576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control first, then Experimental
Description: Control condition is currently marketed sound processing strategy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental first, then Control
Description: Experimental condition is newly modified sound processing strategy.
Study: NCT04647422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of executive functioning and of social cognition processes
Description: Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of executive functioning and of social cognition processes
Description: Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of executive functioning and of social cognition processes
Description: Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of executive functioning and of social cognition processes
Description: Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes
Study: NCT02920203

Intervention type: GENETIC
Intervention: Heart and spleen tissue
Description: genetic sequencing
Study: NCT04062123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Crystalloid IV solution will be infused, with no active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Crystalloid IV solution will be infused, with no active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Crystalloid IV solution will be infused, with no active drug.
Study: NCT02002182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADXS11-001 (ADXS-HPV)
Description: ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
Study: NCT03472703

Intervention type: OTHER
Group type: OTHER
Intervention: Break-Lunch time
Description: The time for the break and lunch will be contrary, depending on their visit/session

Intervention type: OTHER
Group type: OTHER
Intervention: Break-Lunch time
Description: The time for the break and lunch will be contrary, depending on their visit/session
Study: NCT04489420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK001-IV
Description: Planned Starting dose dor IV 1.2x10\^9 cells/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK001-IT
Description: Planned starting dose for IT 200 x10\^6 +/- 50 x10\^6 cells dose
Study: NCT02555462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Ear Measurement system integrated in hearing aid fitting software
Description: The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
Study: NCT04252781

Intervention type: OTHER
Group type: OTHER
Intervention: Exhaustive exploration
Description: * clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index
Study: NCT02753348

Intervention type: OTHER
Intervention: Echocardiography

Intervention type: OTHER
Intervention: Blood analysis from umbilical cord blood

Intervention type: OTHER
Intervention: ECG

Intervention type: OTHER
Intervention: Measurement of oxygen saturation
Study: NCT06668337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Participants in the control group receive a continuous intravenous infusion of normal saline, which serves as an inert placebo with no pharmacological effect. This intervention mimics the administration of the active treatments, allowing for direct comparison with the ephedrine groups to assess the effectiveness of the drug in preventing maternal hypotension during spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
Study: NCT03489057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Education and Resources for Couples (PERC)
Description: PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care plus NCI website
Description: The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
Study: NCT04510311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-[18F]Fluoro-para-hydroxyphenethylguanidine
Description: Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-[18F]Fluoro-para-hydroxyphenethylguanidine
Description: Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [123I] metaiodobenzylguanidine
Description: Single IV injection of 10.0 mCi \[123I\]MIBG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography scan
Description: Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography/computed tomography scan
Description: Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
Study: NCT06668337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
Study: NCT03215511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered as capsules or liquid formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered as capsules or liquid formulation.
Study: NCT04510311

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy scan
Description: Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography/computed tomography scan
Description: SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
Study: NCT05487430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Self-Affirmation
Description: Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
Study: NCT01407354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat treadmill training
Description: Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise therapy
Description: Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session